Memo Therapeutics
Healthcare & Life Sciences
Recent Finacing
Series C
Recent Raise
$27.6M
Memo Therapeutics is a late-stage biotech company that has raised CHF 25M in a Series C funding round to develop its antibody, AntiBKV, and advance its existing antibody pipeline.
Total Funding
$27.6M
Headquarters
Schlieren / Zurich, Switzerland
Founded
N/A
Website
Focus Areas
Biotech
Late-Stage
Antibody Development
Clinical Trials
CMC Manufacturing
Market Entry Preparation
Investors
